Cited by 808Nanoplatforms for cancer theranosticsPhotodynamic Therapy Research StudiesCancer Immunotherapy and Biomarkers

Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer

Open access
Nam, Jutaek, Son, Sejin, Ochyl, Lukasz J., Kuai, Rui, Schwendeman, Anna, Moon, James J.·2018·Nature Communications

Abstract

Photothermal therapy (PTT) is a promising cancer treatment modality, but PTT generally requires direct access to the source of light irradiation, thus precluding its utility against disseminated, metastatic tumors. Here, we demonstrate that PTT combined with chemotherapy can trigger potent anti-tumor immunity against disseminated tumors. Specifically, we have developed polydopamine-coated spiky gold nanoparticles as a new photothermal agent with extensive photothermal stability and efficiency. Strikingly, a single round of PTT combined with a sub-therapeutic dose of doxorubicin can elicit robust anti-tumor immune responses and eliminate local as well as untreated, distant tumors in >85% of animals bearing CT26 colon carcinoma. We also demonstrate their therapeutic efficacy against TC-1 submucosa-lung metastasis, a highly aggressive model for advanced head and neck squamous cell carcinoma (HNSCC). Our study sheds new light on a previously unrecognized, immunological facet of chemo-photothermal therapy and may lead to new therapeutic strategies against advanced cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-03473-9

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • BLI is used to assess nanodrug efficiency based on endogenic luminescence of tumors to confirm NPs diagnostics or theranostic prospects and to integrate with other imaging modalities.

    “BLI is used to assess nanodrug efficiency based on the endogenic luminescence of tumors to confirm NPs diagnostics or theranostic prospects and to integrate with other imaging modalities [19,134,135,136].”

    From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [136]

    The Results section (“Chemo-PTT against advanced head and neck cancer”) uses bioluminescence imaging to assess the efficacy of nanoparticle-based treatment, reporting reduced tumor signals. But the signal came from tumors made with firefly luciferase-expressing cells, not endogenous tumor luminescence. The paper does not establish nanoparticle diagnostic prospects or integration with other imaging modalities. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Nam, J., Son, S., Ochyl, L. J., Kuai, R., Schwendeman, A., & Moon, J. J.
Affiliations
University of Michigan (US)
Corresponding author
Moon, James J.
Venue
Nature Communications
Published
2018-03-14
Volume
9
Issue
1
Pages
1074-1074
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2791998350
Cited by
808
References
59
Citations by year
2026: 43 · 2025: 68 · 2024: 81 · 2023: 86 · 2022: 120 · 2021: 152 · 2020: 127 · 2019: 98 · 2018: 32
FWCI
40.80
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Science Foundation (1553831, R01EB022563, CAREER, R01CA210273, HHSN272201300006C)
  • U.S. Department of Defense (W81XWH1610369, W81XWH)
  • American Heart Association (15PRE25090050)
  • Melanoma Research Alliance (348774)
  • American Foundation for Pharmaceutical Education
  • Johns Hopkins University
  • Emerald Foundation
  • National Institutes of Health (HHSN272201300006C), W81XWH, 1553831)
  • National Cancer Institute (R01CA210273)
  • National Institute of Allergy and Infectious Diseases (HHSN-272201300006C)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB022563)
  • Congressionally Directed Medical Research Programs (W81XWH-16-1-0369)
  • DOD Peer Reviewed Cancer Research Program (W81XWH-16)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
photothermal therapy, chemo-photothermal therapy, antitumor immunity, metastatic cancer, doxorubicin, CT26 cells, lung metastasis, head and neck squamous cell carcinoma, photothermal stability
MeSH terms
Animals, Combined Modality Therapy, Doxorubicin, Drug Therapy, Combination, Humans, Neoplasm Metastasis, Photochemotherapy, Phototherapy, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review